In short

Same molecule, semaglutide, under two brand names for two approved uses at different dose ranges. Ozempic is approved for type 2 diabetes. Wegovy is approved.

By Alsen Walker · Updated September 20, 2026

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

Same molecule, semaglutide, under two brand names for two approved uses at different dose ranges. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management and, separately, for cardiovascular risk reduction in certain adults. Your insurer treats them as entirely different products.

Never take both. Same active ingredient means overlapping them puts a much larger amount in your system at once. If a switch has left you with supply of both, ask your pharmacist rather than using up the surplus.

For how this fits alongside the other comparisons, and what actually decides the choice, see Comparing GLP-1 Medications: How to Actually Choose.

What actually differs

The approved indications, the dose ranges, and the titration schedules. The weight management product goes to higher doses than the diabetes one.

The molecule, the mechanism and the side effect profile are the same. So are the boxed warning and the contraindications.

Why coverage diverges so sharply

Diabetes treatment is a standard covered benefit. Anti-obesity medication is optional, and many employers exclude it entirely.

That single difference explains almost every frustrating conversation people have about these two drugs. It is not about the medicine; it is about which category the indication falls into.

The cardiovascular risk reduction indication matters here, because it sits outside weight management and can open a coverage route that weight management alone does not, including under Medicare Part D where weight loss agents are excluded by statute.

The workaround that is not one

Taking the diabetes-labelled product for weight loss is off-label prescribing. A prescriber can write it. Your plan will not pay for it on that basis, and a prior authorization stating weight loss will be refused.

Asking for a diabetes diagnosis you do not have is a false claim. It stays in your record and can affect life and disability underwriting for years. Any advice suggesting it is advice with your name on the consequences.

Switching between them

Because dose strengths differ, there is often no exact match for where you currently sit. Your prescriber places you at the nearest appropriate step and titrates from there.

Do not work out your own equivalent from a table online. Same molecule does not mean interchangeable milligram for milligram across two products with different approved schedules.

Expect a new prior authorization under separate criteria, and sort it before your current supply runs out.

If you have both diabetes and obesity

Common, and the choice is a clinical one about which indication is primary and what else you are being treated for. Coverage implications are worth raising in that conversation rather than after.

The cardiovascular indication is what changed access here, explained in the SELECT trial and the Medicare Part D route. Switching between the two brands still needs its own authorization.

Frequently asked questions

Is Ozempic just a lower dose of Wegovy?
Same molecule, different approved dose ranges and indications. Not interchangeable administratively.

Can I ask for the diabetes one to save money?
Not if you do not have the indication. Coverage follows the documented diagnosis.

Will one work better for weight?
The weight management product is the one studied and approved for that purpose.

Do I need to re-titrate when switching?
Usually partially. Your prescriber decides.

Are side effects the same?
Same molecule, same profile, with dose influencing severity.

Why did my plan cover one and refuse the other?
Different products, different criteria, and weight management is often excluded as a benefit.

Sources and further reading

  1. Novo Nordisk. Wegovy (semaglutide) injection: US Prescribing Information. www.novo-pi.com
  2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov
  3. Novo Nordisk. Ozempic (semaglutide) injection: US Prescribing Information. www.novo-pi.com
  4. MedlinePlus (US National Library of Medicine). Semaglutide injection: drug information. medlineplus.gov
  5. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Prescription medications to treat overweight and obesity. www.niddk.nih.gov

GLP1Hub content is for general information and is not medical advice. Prices and coverage rules change often, so confirm current details with the provider, your insurer and your prescriber. See our editorial standards and medical disclaimer.

More in Comparisons

All Comparisons guides →

Alsen Walker is a health writer and researcher at GLP1Hub with five years of experience researching and writing health and medical content. He works in a medical-field role alongside his undergraduate studies. At GLP1Hub he researches GLP-1 weight loss programs, pricing and insurance rules, and checks claims against FDA prescribing information, published clinical trials and official government sources. Alsen is not a physician, and his articles are general information, not medical advice.